SG/PUT/BRISTOL-MYERS SQUIBB/50/0.1/21.03.25

SG/PUT/BRISTOL-MYERS SQUIBB/50/0.1/21.03.25 Stock

DE000SU6Q4C8

Market Closed - Boerse Frankfurt Warrants 03:39:12 2024-06-17 pm EDT
0.95 ^EUR	+3.26%

1 month	+33.80%
3 months	+150.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/PUT/BRISTOL-MYERS SQUIBB/50/0.1/21.03.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment	Jun. 14	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	Jun. 13	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	Jun. 13	DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	Jun. 13	BU

More news

Quotes 5-day view

Date	Price	Change
24-06-17	0.95	+3.26%
24-06-14	0.92	+1.10%
24-06-13	0.91	+10.98%
24-06-12	0.82	+3.80%
24-06-11	0.79	-3.66%

Real-time Boerse Frankfurt Warrants

Last update June 17, 2024 at 03:39 pm EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SU6Q4C
ISIN	DE000SU6Q4C8
Date issued	2024-01-08
Strike	50 $
Maturity	2025-03-21 (277 Days)
Parity	10 : 1
Emission price	0.46 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.02 €
Lowest since issue	0.29 €
Spread	0.01 €
Spread %	1.04%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company